Literature summary for 1.14.11.54 extracted from

Esteve-Puig, R.; Climent, F.; Pineyro, D.; Domingo-Domenech, E.; Davalos, V.; Encuentra, M.; Rea, A.; Espejo-Herrera, N.; Soler, M.; Lopez, M.; Ortiz-Barahona, V.; Tapia, G.; Navarro, J.; Cid, J.; Farre, L.; Villanueva, A.; Casanova, I.; Mangues, R.
Epigenetic loss of m1A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome (2021), Blood, 137, 994-999 .

Search for more literature for 1.14.11.54

Application

Application	Comment	Organism
medicine	ALKBH3 promoter CpG island hypermethylation is most frequent in Hodgkin lymphoma cell lines (44%; 4 of 9), followed by Burkitt lymphoma (38%; 5 of 13), other non-Hodgkin lymphoma cell lines (37%; 12 of 32), and anaplastic large cell lymphoma. ALKBH3 promoter hypermethylation is detected in detected in18% (14 of 80) of the primary Hodgkin lymphoma cases. ALKBH3 CpG island hypermethylation is associated with protein loss. ALKBH3 epigenetic silencing is also associated with COL1A2 and COL1A1 overexpression, whereas an unmethylated ALKBH3 CpG island is linked to the absence of collagen expression. ALKBH3 hypermethylation is associated with shorter overall survival in the studied Hodgkin lymphoma cohort	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	Q96Q83	-	-

Synonyms

Synonyms	Comment	Organism
ALKBH3	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)